Scandinavian ChemoTech concludes the year with receiving an order from the Philippines

Scandinavian ChemoTech AB has received an order from Basemed Kare Inc. in the Philippines, an order worth EUR 17,000.

The order placed will firstly be used for the Basemed's leasing business but is also intended for conducting future studies in the Philippines.

"It is gratifying that Basemed's work during the autumn has started to generate success in the leasing business, and furthermore that they put great effort in establishing more studies, which creates very good conditions for 2020." - Mohan Frick, CEO of ChemoTech.

"You can't claim to have a complete cancer clinic without offering IQwave™ and D-EECT treatments," - Dr. Jim Rojo, KOL and Medical Oncologist, who frequently treats patients in the Philippines with IQwave™.

For more information, please contact:
Mohan Frick, Co-Founder and CEO

+46 (0)10-218 93 00
info@chemotech.se

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation. The information was submitted by the agency of above stated contact person, to be made public on Friday 20th of December 2019 at 09.00 (CET).

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se.